140 related articles for article (PubMed ID: 11903102)
1. Influence of benzodiazepines on antiparkinsonian drug treatment in levodopa users.
van de Vijver DA; Roos RA; Jansen PA; Porsius AJ; de Boer A
Acta Neurol Scand; 2002 Jan; 105(1):8-12. PubMed ID: 11903102
[TBL] [Abstract][Full Text] [Related]
2. Decrease of antiparkinsonian drugs before start of an antipsychotic in patients on levodopa treatment?
van de Vijver DA; Roos RA; Jansen PA; Porsius AJ; de Boer A
Pharm World Sci; 2004 Oct; 26(5):277-81. PubMed ID: 15598069
[TBL] [Abstract][Full Text] [Related]
3. Start of a selective serotonin reuptake inhibitor (SSRI) and increase of antiparkinsonian drug treatment in patients on levodopa.
van de Vijver DA; Roos RA; Jansen PA; Porsius AJ; de Boer A
Br J Clin Pharmacol; 2002 Aug; 54(2):168-70. PubMed ID: 12207636
[TBL] [Abstract][Full Text] [Related]
4. Influence of initial use of serotonergic antidepressants on antiparkinsonian drug use in levodopa-using patients.
Arbouw ME; Movig KL; Neef C; Guchelaar HJ; Egberts TC
Eur J Clin Pharmacol; 2007 Feb; 63(2):181-7. PubMed ID: 17200834
[TBL] [Abstract][Full Text] [Related]
5. Concentration-effect relationship of levodopa in patients with Parkinson's disease.
Harder S; Baas H; Rietbrock S
Clin Pharmacokinet; 1995 Oct; 29(4):243-56. PubMed ID: 8549026
[TBL] [Abstract][Full Text] [Related]
6. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
[TBL] [Abstract][Full Text] [Related]
7. CQA 206-291: a novel dopamine agonist in the treatment of Parkinson's disease.
Rascol O; Fabre N; Teräväinen H; Poewe W; Lücking C; Rinne U; Dupont E; Hirt D; Hoyer M; Lataste X
Clin Neuropharmacol; 1990 Aug; 13(4):303-11. PubMed ID: 2208182
[TBL] [Abstract][Full Text] [Related]
8. [Outpatient establishment and initial management of treatment with intraduodenal levodopa-carbidopa infusion in advanced Parkinson's disease].
Fernandez-Pajarin G; Ares-Pensado B; Sesar A; Iglesias-Canle J; Masa-Vazquez L; Castro A
Rev Neurol; 2018 Jul; 67(1):1-5. PubMed ID: 29923594
[TBL] [Abstract][Full Text] [Related]
9. Basal ganglia, Parkinson's disease and levodopa therapy. Proceedings of a meeting. St Thomas, Virgin Islands, January 2000.
Trends Neurosci; 2000 Oct; 23(10 Suppl):S1-126. PubMed ID: 11221749
[No Abstract] [Full Text] [Related]
10. Pharmacokinetics and pharmacodynamics of levodopa.
Nutt JG
Mov Disord; 2008; 23 Suppl 3():S580-4. PubMed ID: 18781675
[TBL] [Abstract][Full Text] [Related]
11. The neurochemistry of therapeutics: levodopa pharmacodynamics in Parkinson's disease.
Frey KA
Ann Neurol; 2001 Mar; 49(3):285-7. PubMed ID: 11261500
[No Abstract] [Full Text] [Related]
12. Sustained release antiparkinson agents: controlled release levodopa.
Gauthier S; Amyot D
Can J Neurol Sci; 1992 Feb; 19(1 Suppl):153-5. PubMed ID: 1571861
[TBL] [Abstract][Full Text] [Related]
13. [Optimisation of treatment of Parkinson's disease with levodopa].
Białecka M; Adamiak U; Gawrońska-Szklarz B
Neurol Neurochir Pol; 2009; 43(5):446-59. PubMed ID: 20054747
[TBL] [Abstract][Full Text] [Related]
14. Comparison of 200 mg retarded release levodopa/carbidopa - with 150 mg levodopa/carbidopa/entacapone application: pharmacokinetics and efficacy in patients with Parkinson's disease.
Müller T; Ander L; Kolf K; Woitalla D; Muhlack S
J Neural Transm (Vienna); 2007; 114(11):1457-62. PubMed ID: 17564755
[TBL] [Abstract][Full Text] [Related]
15. Caffeine; the Forgotten Potential for Parkinson's Disease.
Negida A; Elfil M; Attia ; Farahat E; Gabr M; Essam A; Attia D; Ahmed H
CNS Neurol Disord Drug Targets; 2017; 16(6):652-657. PubMed ID: 27823571
[TBL] [Abstract][Full Text] [Related]
16. Effects of caffeine on levodopa pharmacokinetics and pharmacodynamics in Parkinson disease.
Deleu D; Jacob P; Chand P; Sarre S; Colwell A
Neurology; 2006 Sep; 67(5):897-9. PubMed ID: 16966563
[TBL] [Abstract][Full Text] [Related]
17. Antipsychotics and Parkinson's disease: association with disease and drug choice during the first 5 years of antiparkinsonian drug treatment.
van de Vijver DA; Roos RA; Jansen PA; Porsius AJ; de Boer A
Eur J Clin Pharmacol; 2002 May; 58(2):157-61. PubMed ID: 12012150
[TBL] [Abstract][Full Text] [Related]
18. Gastrointestinal surgical procedures affect levodopa pharmacokinetics in Parkinson's disease.
Miyaue N; Yabe H; Nagai M; Nomoto M
Parkinsonism Relat Disord; 2020 Jul; 76():29-31. PubMed ID: 32559630
[No Abstract] [Full Text] [Related]
19. Levodopa for Parkinson's disease.
Gérard JM; Elosegi JA
N Engl J Med; 2009 Feb; 360(9):936; author reply 936. PubMed ID: 19256032
[No Abstract] [Full Text] [Related]
20. Controlled-release carbidopa/levodopa (CR) in parkinsonian patients with response fluctuations on standard levodopa treatment: clinical and pharmacokinetic observations.
Deleu D; Jacques M; Michotte Y; Ebinger G
Neurology; 1989 Nov; 39(11 Suppl 2):88-92; discussion 95. PubMed ID: 2685654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
